论文部分内容阅读
目的观察减重药西布曲明对肥胖患者糖脂代谢、全身总脂量、腹内脂肪(IAFA)及胰岛素抵抗(IR)的影响。方法采用随机双盲双模拟、安慰剂对照、多中心临床试验。359例不伴高血压和糖尿病,体重指数≥27kg/m2的肥胖患者被随机分入西布曲明片或胶囊组或安慰剂组。西布曲明初始剂量为10mg/d,疗效不明显者加至20mg/d,疗程24周。结果西布曲明片和胶囊组治疗前后平均体重分别减轻4·86kg和4·68kg(P<0·05),空腹血糖及血脂有一定改善,HOMA-IR指数分别由5·32和5·09降至3·32和3·12(P<0·05);全身总脂量分别减少4·07kg和4·09kg(P<0·05),IAFA分别减少19·21%和16·98%(P<0·05);上述指标在安慰剂组改变不如西布曲明组明显。结论西布曲明有一定的纠正肥胖者糖脂代谢紊乱,减少脂肪特别是IAFA的作用,在一定程度上减轻IR。
Objective To observe the effects of sibutramine, a traditional Chinese herbal medicine, on glucose and lipid metabolism, total body fat, abdominal fat (IAFA) and insulin resistance (IR) in obese patients. Methods A randomized, double-blind, double-dummy, placebo-controlled, multicentre clinical trial was performed. 359 obese patients without hypertension and diabetes with a body mass index> 27 kg / m2 were randomized to either sibutramine or capsule or placebo. The initial dose of sibutramine 10mg / d, no significant effect was added to 20mg / d, treatment for 24 weeks. Results The mean body weight of sibutramine capsule and capsule group before and after treatment decreased by 4.86kg and 4.68kg respectively (P <0.05), and the fasting blood glucose and blood lipids improved slightly. The HOMA-IR index decreased from 5.32 and 5.70 09 decreased to 3.32 and 3.12 respectively (P <0.05); the total body fat decreased by 4. 07kg and 4. 09kg (P <0.05), the IAFA decreased by 19.21% and 16.98 % (P <0.05). The above indexes were not as obvious in the placebo group as those in the sibutramine group. Conclusion Sibutramine may correct the disorder of glucose and lipid metabolism in obese people and reduce the effect of fat, especially IAFA, to a certain extent, reduce IR.